Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23060412 | 0.92 | POLB (0.65) | F2RGAAPOLBATML3MBTL1 | |
| SCHEMBL26623450 | 0.90 | POLB (0.60) | F2RGAAPOLBATML3MBTL1 | |
| SCHEMBL26637874 | 0.89 | L3MBTL1 (0.59) | F2RGAAPOLBATML3MBTL1 | |
| SCHEMBL24939298 | 0.88 | ALDH1A1 (0.53) | F2RGAAMAPK1POLBATM | |
| SCHEMBL16291113 | 0.86 | GAA (0.54) | GAAPOLBL3MBTL1ALDH1A1LMNA | |
| SCHEMBL5904019 | 0.82 | GAA (0.50) | GAAMAPK1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL29678574 | 0.82 | GAA (0.50) | GAAMAPK1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL9474879 | 0.82 | ADRA2C (0.61) | GAAPOLBL3MBTL1ALDH1A1LMNA | |
| SCHEMBL27137230 | 0.82 | GAA (0.50) | GAAPOLBL3MBTL1ALDH1A1LMNA | |
| SCHEMBL5183678 | 0.81 | ALDH1A1 (0.72) | GAAMAPK1MTNR1BPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | DDT, ACHE, AHR | F2R 2066/4885GAA 4686/4885MAPK1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.